Brief: Arcutis Biotherapeutics Q3 basic EPS USD -0.73
03/11/2023 11:36
Nov 3 (Reuters) - Arcutis Biotherapeutics Q3 product revenue USD 8.109 million. * Q3 basic EPS USD -0.73 * Q3 net income USD -44.765 million * Q3 operating expenses USD 75.013 million * Q3 operating income USD -36.904 million
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf